Adjunctive corticosteroid therapy is safe for bacterial corneal ulcers

Article

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA)Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA).

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA), claims a study in the Archives of Ophthalmology.

Dr Muthiah Srinvasan and his team, Department of Corneal and External Diseases, Aravind Eye Care System, Madurai, India, conducted a randomized, placebo-controlled, double-masked multicentered clinical trial on 1769 patients with bacterial corneal ulcers. All patients were screened between September 1, 2006 and February 22, 2010.

The primary outcome was BSCVA at 3 months from patient enrolment and the secondary outcomes were infiltrate/scar size, re-epithelialization and corneal perforation.

In the subgroups of baseline BSCVA and ulcer location there were a significant number of corticosteroids observed. There was no significant difference in the 3-month BSCVA infiltrate scar/size, time to re-epithelialization and corneal perforation.

Patients with vision of counting fingers or worse at baseline presented with 0.17 logMAR better visual acuity with corticosteroids. Patients that were at baseline had 0.20 logMAR better visual acuity with corticosteroids.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.